Unravelling the link between diabetes and heart disease

Research Updates

Researchers at The Heart Research Institute are the first in the world to uncover a link between diabetes and cardiovascular disease, a discovery that has the potential to save millions of lives.

More than 65 per cent of diabetics die from heart and vascular disease.

This includes heart attack, peripheral artery disease and stroke. Diabetics are also up to six times more likely to suffer from atherosclerosis than people without diabetes.

In breakthrough research, a team of cardiologists and researchers from The Heart Research Institute and Royal Prince Alfred (RPA) Hospital uncovered a direct mechanism by which the high sugar levels in diabetes causes vascular damage. They found that high glucose levels in diabetes directly interfered with the regulation of a protein called Thioredoxin Interacting Protein, or TXNIP, one of the most glucose-sensitive genes in the entire human genome.

“Vascular disease in diabetes is hallmarked by the development of impaired function of the endothelium, a critically important layer of cells that lines the blood vessel walls and serves to protect blood vessels from injury and disease,” said Associate Professor Martin Ng, Head of the Translational Research and Bioengineering Group at The Heart Research Institute and interventional cardiologist at RPA.  

“Our work is tremendously exciting because it identifies, for the first time, how high glucose can directly contribute to vascular disease in diabetes and it identifies a new target for therapy,” Professor Ng said.

“We found that by interfering with TXNIP, high-glucose levels are able to directly interfere with endothelial cell function and cause endothelial cell death - key hallmarks of the cardiovascular disease of diabetes.

“By preventing high glucose-mediated interference with TXNIP, we were able to strikingly rescue the endothelial cell dysfunction of diabetes,” Associate Professor Ng said.

The team, which will have its ground-breaking work published this week in Diabetes, the official journal of the American Diabetes Association, has also been awarded a new grant from the National Health and Medical Research Council to investigate a drug that prevents diabetic vascular disease through TXNIP with the aim of developing new, more effective therapies.

Previous
Next

Related news

Stopping atherosclerosis in its tracks

A new treatment for atherosclerosis could soon be in sight, with an HRI study finding that progression of the common condition could be slowed using the chemokine binding protein ‘M3’.
Read more

Will a fitness tracker help you reach your health and fitness goals?

It’s hard to deny the growing trend of wearable activity and fitness trackers. If you pay close attention to the wrist of the person next to you, chances are you’ll find they’re not just keeping track of the time, but their daily step count, energy expenditure, heart rate or sleep quality.

Read more

Dr Anna Waterhouse joins HRI as Group Leader

The HRI is pleased to welcome Dr Anna Waterhouse as Group Leader of the Cardiovascular Medical Devices Group and Senior Lecturer at the University of Sydney. Dr Waterhouse’s research focuses on how medical devices – such as artificial hearts, stents and bypass machines – interact with the body. Her aim is to understand the interactions of medical devices with patients’ blood, proteins and cells to develop more sophisticated and compatible materials. 

Read more